Join us as we identify and discuss key takeaways from the Focus on HFSA Scientific Statement on Cardio-Oncology and Heart Failure. A Focus on Key Takeaways, utilizing a Case-Based Discussion of the Statement.
This activity is intended for trainees, fellows, mid-career physicians, APPs, nurses, and intensivists.
At the conclusion of this activity, learners will be better able to:
- Recognize the lack of uniform guidelines and the need for standardized cardiac monitoring in cancer therapies beyond anthracyclines and trastuzumab.
- Explain the evolving concept of permissive cardiotoxicity and how it may allow continued cancer treatment while managing cardiac risk in high-risk patients.
- Identify urgent treatment steps for ICI-associated myocarditis and explore therapies beyond corticosteroids.
- Discuss heart transplant eligibility in cancer patients, emphasizing a personalized approach.
Program Agenda
All sessions are listed in Eastern Standard Time.
Welcome Remarks and Event Background
Michelle Bloom, MD and Ana Barac, MD, PhD
Case Presentation #1 and Panel Discussion
Daniel Lenihan, MD & Panelists
A Case of Lung Malignancy and EGFR Tyrosine Kinase Inhibitor Induced Cardiomyopathy Patient with Lung Cancer and Osimertinib who develops cardiomyopathy
Case Presentation #2 and Panel Discussion
Ana Barac, MD & Panelists
A Case of Metastatic Breast Cancer Complicated by the Development of Heart Failure
Case Presentation #3 and Panel Discussion
Nicolas Palaskas ,MD & Panelists
A Case of Metastatic Prostate Cancer and Fulminant Immune Checkpoint Inhibitor-Related Myocarditis
Case Presentation #4 and Panel Discussion
Alana Ferrari, PharmD, BCOP & Panelists
A Case of Chronic Lymphocytic Leukemia and Bruton Tyrosine Kinase Inhibitor-Associated Cardiomyopathy
Case Presentation #5 and Panel Discussion
Anju Nohria, MD, MSc & Panelists
A Case of Recent Malignancy and Consideration for Advanced HF Therapies
Closing Remarks
Michelle Bloom, MD and Ana Barac, MD, PhD